#IMS2024: Newly diagnosed multiple myeloma

To update you on the exciting content presented at the 21st International Myeloma Society (IMS) Annual Meeting, we have collated our social media coverage. Catch up with our live social media posts relating to newly diagnosed multiple myeloma here.  

CONGRESS | #IMS2024 | PRESENTATION

Aurore Perrot @PerrotAurore presents an interim analysis of the IFM2020-02 MIDAS study investigating the efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible NDMM (N=791 included; N=575 completed… pic.twitter.com/SVQLEDAFxB

— Multiple Myeloma Hub (@MM_Hub) September 29, 2024

CONGRESS | #IMS2024 | PRESENTATION

Ashraf Badros shares primary results from the phase III AURIGA study comparing subcutaneous daratumumab (Dara) + lenalidomide (R) with R monotherapy as maintenance therapy in NDMM after transplant (N=200).

Dara-R more than doubled the MRD… pic.twitter.com/9hbsd024ar

— Multiple Myeloma Hub (@MM_Hub) September 28, 2024

CONGRESS | #IMS2024 | PRESENTATION

Saad Usmani @szusmani shares findings from the phase III CEPHEUS study comparimg daratumumab + bortezomib/lenalidomide/dexamethasone (Dara-VRd) with VRd in patients with transplant-ineligible (TIE) or transplant-deferred NDMM (N=395).

The… pic.twitter.com/ShsUauVFmg

— Multiple Myeloma Hub (@MM_Hub) September 28, 2024

CONGRESS | #IMS2024 | PRESENTATION

Paula Rodriguez-Otero @paurotero shares findings from the phase II dose expansion cohort (cohort K) of the phase I/II CC-220 MM-001 trial which investigated iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible (TNE) NDMM… pic.twitter.com/yzs0tuO36p

— Multiple Myeloma Hub (@MM_Hub) September 28, 2024

CONGRESS | #IMS2024 | PRESENTATION

Xavier Leleu @ shares findings from the phase III BENEFIT study comparing isatuximab plus VRd vs ISA-Rd in patients with transplant ineligible NDMM (N = 270).

Isa-VRd resulted in deep response rates vs Isa-Rd, with a significant improvement in… pic.twitter.com/foul9xM0M7

— Multiple Myeloma Hub (@MM_Hub) September 28, 2024

CONGRESS | #IMS2024 | PRESENTATION

Meletios Dimopoulos @thanosdimop shares findings from the phase III IMROZ trial comparing Isa-VRd with VRd for transplant-ineligible patients with NDMM (N = 446).

At a median follow-up of 5 years, Isa-VRd followed by Isa-Rd led to a… pic.twitter.com/3D2TrqBjN2

— Multiple Myeloma Hub (@MM_Hub) September 28, 2024

CONGRESS | #IMS2024 | PRESENTATION

Lisa Leypoldt shares findings from a 4-year follow-up of Isa-KRd in high-risk NDMM from the phase II GMMG-CONCEPT trail (N = 153).

With >4-year follow-up, Isa-KRd-induced MRD-negative remissions rose to 83.5% of transplant eligible and 69.2%… pic.twitter.com/BDolvcxtaO

— Multiple Myeloma Hub (@MM_Hub) September 26, 2024

CONGRESS | #IMS2024 | PRESENTATION

Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709), which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and consolidation… pic.twitter.com/42G8mmVmPt

— Multiple Myeloma Hub (@MM_Hub) September 26, 2024

CONGRESS | #IMS2024 | PRESENTATION

Jill Corre shares an MRD update from the phase III CASSIOPEIA trial (N = 1085), which established D-VTd as a standard of care for transplant eligible NDMM.

Extended follow-up demonstrated that DARA-based induction/consolidation and maintenance… pic.twitter.com/7tfJIewuYY

— Multiple Myeloma Hub (@MM_Hub) September 26, 2024

CONGRESS | #IMS2024 | PRESENTATION

Jill Corre shares an MRD update from the phase III CASSIOPEIA trial (N = 1085), which established D-VTd as a standard of care for transplant eligible NDMM.

Extended follow-up demonstrated that DARA-based induction/consolidation and maintenance… pic.twitter.com/7tfJIewuYY

— Multiple Myeloma Hub (@MM_Hub) September 26, 2024

Abstract #64
CONGRESS | #IMS2024 | PRESENTATION

Verónica González-Calle @Vero_Glez_Calle shares findings from the phase II GEM-BELA-VRd trial which investigated belantamab mafodotin (belamaf) + VRd for the treatment of newly diagnosed transplant eligible MM (N = 50).

The safety… pic.twitter.com/Wf0OnOJKU7

— Multiple Myeloma Hub (@MM_Hub) September 25, 2024

CONGRESS | #IMS2024 | PRESENTATION

Ajay Nooka @AjayNookaMD reviews optimal consolidation and maintenance strategies for NDMM post-ASCT.

Lenalidomide maintenance remains the standard of care for standard risk MM, with combination strategies preferred for high-risk patients. MRD… pic.twitter.com/HxRyNMN4Yy

— Multiple Myeloma Hub (@MM_Hub) September 25, 2024

CONGRESS | #IMS2024 | PRESENTATION

Francesca Gay outlines the goals of induction therapy in transplant eligible myeloma patients and summarizes key trial data.

Findings support the use of quadruplet therapy (anti-CD38 + PI + IMID + DEX) as a safe and effective choice; with high… pic.twitter.com/I0gAGkXcPh

— Multiple Myeloma Hub (@MM_Hub) September 25, 2024